Fig. 5: Progression-free survival (PFS) and overall survival (OS) of patients treated with molecularly targeted agents (MTAs) in different digital drug-assignment (DDA) AEL score tiers. | npj Precision Oncology

Fig. 5: Progression-free survival (PFS) and overall survival (OS) of patients treated with molecularly targeted agents (MTAs) in different digital drug-assignment (DDA) AEL score tiers.

From: A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial

Fig. 5: Progression-free survival (PFS) and overall survival (OS) of patients treated with molecularly targeted agents (MTAs) in different digital drug-assignment (DDA) AEL score tiers.

Kaplan–Meier estimates of a progression-free survival (PFS) and b overall survival (OS) of patients treated with matched molecularly targeted therapy in SHIVA01 according to DDA AEL tiers.

Back to article page